Mammalian target of rapamycin and diabetes: what does the current evidence tell us? (Q37570804)

21 August 2017

Mammalian target of rapamycin and diabetes: what does the current evidence tell us? (English)

1 reference

21 August 2017

1 reference

B Vodenik

1

1 reference

21 August 2017

J Rovira

series ordinal

2

1 reference

21 August 2017

J M Campistol

series ordinal

3

1 reference

21 August 2017

language of work or name

English

0 references

publication date

19 July 2009

1 reference

Transplantation Proceedings

21 August 2017

1 reference

21 August 2017

41

1 reference

21 August 2017

S31-8

1 reference

21 August 2017

6 Suppl

1 reference

Diabetes mellitus after renal transplantation: as deleterious as non-transplant-associated diabetes?

21 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2009.06.159

Diabetes mellitus after kidney transplantation in the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2009.06.159

Incidence and risk factors of new-onset diabetes mellitus after renal transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2009.06.159

Patient survival after renal transplantation: IV. Impact of post-transplant diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2009.06.159

Posttransplant diabetes is a cardiovascular risk factor in renal transplant patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2009.06.159

The impact of early-diagnosed new-onset post-transplantation diabetes mellitus on survival and major cardiac events

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2009.06.159

New onset hyperglycemia and diabetes are associated with increased cardiovascular risk after kidney transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2009.06.159

Clinical impact of posttransplant diabetes mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2009.06.159

Insulin resistance and insulin deficiency in the pathogenesis of posttransplantation diabetes in man

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2009.06.159

Insulin signalling and the regulation of glucose and lipid metabolism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2009.06.159

Ser/Thr phosphorylation of IRS proteins: a molecular basis for insulin resistance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2009.06.159

Clinical and genetic risk factors for posttransplant diabetes mellitus in adult renal transplant recipients treated with tacrolimus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2009.06.159

Post-transplant diabetes mellitus: a case-control analysis of the risk factors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2009.06.159

Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2009.06.159

Glucose intolerance after renal transplantation depends upon prednisolone dose and recipient age.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2009.06.159

Posttransplantation diabetes mellitus in FK-506-treated renal transplant recipients: analysis of incidence and risk factors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2009.06.159

New-onset diabetes mellitus in transplant patients: pathogenesis, complications, and management

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2009.06.159

Determinants of insulin resistance in renal transplant recipients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2009.06.159

Inhibition of human insulin gene transcription by the immunosuppressive drugs cyclosporin A and tacrolimus in primary, mature islets of transgenic mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2009.06.159

Posttransplant diabetes mellitus in kidney transplant recipients receiving calcineurin or mTOR inhibitor drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2009.06.159

Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2009.06.159

Nutrient overload, insulin resistance, and ribosomal protein S6 kinase 1, S6K1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2009.06.159

Nutrient sensor links obesity with diabetes risk

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2009.06.159

Inappropriate activation of the TSC/Rheb/mTOR/S6K cassette induces IRS1/2 depletion, insulin resistance, and cell survival deficiencies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2009.06.159

Upregulation of the mammalian target of rapamycin complex 1 pathway by Ras homolog enriched in brain in pancreatic beta-cells leads to increased beta-cell mass and prevention of hyperglycemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2009.06.159

Mammalian Target of Rapamycin Pathway Blockade Slows Progression of Diabetic Kidney Disease in Rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2009.06.159

New-onset diabetes mellitus after kidney transplantation: the role of immunosuppression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2009.06.159

Sirolimus is associated with new-onset diabetes in kidney transplant recipients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2009.06.159

Rapamycin Has a Deleterious Effect on MIN-6 Cells and Rat and Human Islets

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2009.06.159

Hyperglycemia-induced beta-cell apoptosis in pancreatic islets of Psammomys obesus during development of diabetes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2009.06.159

Monounsaturated fatty acids prevent the deleterious effects of palmitate and high glucose on human pancreatic beta-cell turnover and function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2009.06.159

IRS-3 inhibits IRS-2-mediated signaling in pancreatic beta-cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2009.06.159

Differential activation mechanisms of Erk-1/2 and p70(S6K) by glucose in pancreatic beta-cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2009.06.159

Decreasing IRS-2 expression in pancreatic β-cells (INS-1) promotes apoptosis, which can be compensated for by introduction of IRS-4 expression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2009.06.159

Protein kinase B/Akt prevents fatty acid-induced apoptosis in pancreatic beta-cells (INS-1).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2009.06.159

Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2009.06.159

Five-year follow-up after clinical islet transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2009.06.159

Sirolimus toxicity and vascular endothelial growth factor release from islet and renal cell lines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2009.06.159

Activation of IRS-2-mediated signal transduction by IGF-1, but not TGF-alpha or EGF, augments pancreatic beta-cell proliferation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2009.06.159

Upregulation of insulin receptor substrate-2 in pancreatic beta cells prevents diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2009.06.159

Insulin receptor substrate-2 proteasomal degradation mediated by a mammalian target of rapamycin (mTOR)-induced negative feedback down-regulates protein kinase B-mediated signaling pathway in beta-cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2009.06.159

mTORC1 activation regulates beta-cell mass and proliferation by modulation of cyclin D2 synthesis and stability

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2009.06.159

Glucose metabolism in renal transplant recipients: effect of calcineurin inhibitor withdrawal and conversion to sirolimus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2009.06.159

The metabolic impact of rapamycin (sirolimus) in chronic canine islet graft recipients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2009.06.159

Vascular endothelial growth factor as a survival factor for human islets: effect of immunosuppressive drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2009.06.159

Inhibitory effects of immunosuppressive drugs on insulin secretion from HIT-T15 cells and Wistar rat islets

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2009.06.159

Rapamycin impairs beta-cell proliferation in vivo.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2009.06.159

The role of mTOR in the adaptation and failure of beta-cells in type 2 diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2009.06.159

MAP kinases and mTOR mediate insulin-induced phosphorylation of insulin receptor substrate-1 on serine residues 307, 612 and 632

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2009.06.159

Regulation of insulin signalling by hyperinsulinaemia: role of IRS-1/2 serine phosphorylation and the mTOR/p70 S6K pathway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2009.06.159

Absence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2009.06.159

Amino acid-sensing mTOR signaling is involved in modulation of lipolysis by chronic insulin treatment in adipocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2009.06.159

Effect of mTOR inhibitor on body weight: from an experimental rat model to human transplant patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2009.06.159

Non-alcoholic steatohepatitis and metabolic syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2009.06.159

The mammalian target of rapamycin regulates lipid metabolism in primary cultures of rat hepatocytes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2009.06.159

Sustained activation of the mammalian target of rapamycin nutrient sensing pathway is associated with hepatic insulin resistance, but not with steatosis, in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2009.06.159

PTEN down-regulation by unsaturated fatty acids triggers hepatic steatosis via an NF-kappaBp65/mTOR-dependent mechanism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2009.06.159

Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2009.06.159

Increased activation of the mammalian target of rapamycin pathway in liver and skeletal muscle of obese rats: possible involvement in obesity-linked insulin resistance.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2009.06.159

Quantitation of muscle glycogen synthesis in normal subjects and subjects with non-insulin-dependent diabetes by 13C nuclear magnetic resonance spectroscopy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2009.06.159

Molecular mechanisms of lipid-induced insulin resistance in muscle, liver and vasculature.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2009.06.159

The Mammalian target of rapamycin pathway regulates nutrient-sensitive glucose uptake in man

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2009.06.159

Rapamycin does not improve insulin sensitivity despite elevated mammalian target of rapamycin complex 1 activity in muscles of ob/ob mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2009.06.159

Reduced activation of phosphatidylinositol-3 kinase and increased serine 636 phosphorylation of insulin receptor substrate-1 in primary culture of skeletal muscle cells from patients with type 2 diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2009.06.159

10.1016/J.TRANSPROCEED.2009.06.159

7 January 2021

Identifiers

DOI

1 reference

21 August 2017

1 reference